Loading stock data…
TransMedics Group (TMDX)
$88.27-1.71 (-1.90%)
After Hours$88.25-0.02 (-0.02%)· Last close Sep 8
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
TransMedics Group, Inc. in the Healthcare sector is trading at $88.27 with a market capitalization of $2.6B. Wall Street consensus targets $97.30 (10 analysts), implying a +10.2% move over the next 12 months. The stock is currently 43% below its 52-week high of $156.00, remaining 15.6% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +10.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $173.93M↑ | $160.76M↑ | $143.82M↓ | $157.37M↑ | $143.54M |
| Gross Profit | $101.16M↑ | $93.41M↑ | $84.58M↓ | $96.59M↑ | $88.23M |
| Operating Income | $13.30M↓ | $21.27M↓ | $23.30M↓ | $36.57M↑ | $27.44M |
| Net Income | $7.32M↓ | $105.38M↑ | $24.32M↓ | $34.91M↑ | $25.68M |
Peer Comparison
JNJUNHPFE
Fundamentals
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a po...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.62B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
34.80%
Volume
Today's trading volume
593,836
Recent News
Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure?
TransMedics' rapid revenue growth and cheaper valuation face rising margin pressure as heavy investment raises execution risks.
Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?
TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
TransMedics Targets $2B Opportunity With Kidney Push, European Expansion
TransMedics Group (NASDAQ:TMDX) outlined its growth strategy at Canaccord Genuity’s 46th Annual Global Growth Conference, highlighting investments in kidney transplantation, European expansion, next-generation technology and broader adoption in heart and lung transplantation. Waleed Hassanein, Tran
TransMedics (TMDX) Q2 2026 Earnings Call Transcript
Revenue hit $189.9 million with 21% growth as organ transplant volumes surge.
TransMedics Stock Dips Post Q2 Earnings Miss, Margins Contract
TMDX's Q2 revenue beat and raised outlook are overshadowed by earnings miss, declining margins and sharply higher operating costs.